View Cart  

Genentech Gets Untitled Letter for Misleading Claims in Oncology Drug Promo

A A
The FDA has issued an untitled letter to Genentech for educational aids aimed at healthcare professionals that overstate the efficacy and minimize the risks of its cancer drug Tarceva.

To View This Article:

Login

Subscribe To Drug Industry Daily